The "rule of 5" has become a mainstay of decision-making in the pharmaceutical industry as well as in nonindustrial (academic and institutional) drug development. However the authors of the original paper never intended for "double cutoffs" to preclude development of new drug leads for parasitic diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473536 | PMC |
| http://dx.doi.org/10.1016/j.ijpddr.2017.05.003 | DOI Listing |
Publication Analysis
Top Keywords
drug development
8
rule impede
4
impede anti-parasitic
4
anti-parasitic drug
4
development "rule
4
"rule mainstay
4
mainstay decision-making
4
decision-making pharmaceutical
4
pharmaceutical industry
4
industry well
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!